NBDA Leadership/Management Team

The NBDA team brings unprecedented experience and expertise in all aspects of biomarker discovery, development, regulatory science, and commercialization to achieve its mission. The NBDA team has deep experience in major large-scale scientific initiatives, bio-specimens and bio-repository research and development, bioinformatics and computational modeling, drug and diagnostics development, advanced technologies, and executive leadership. The management construct will operate at scale through knowledge networks of experts from the affected biomarker communities.  The NBDA governance includes Steering and Scientific Advisory Committees.


Anna D. BarkerAnna D. Barker, Ph.D., Director and President, works with the NBDA leadership team, external experts, and stakeholders to define the scope and targeted projects and programs for the Alliance. Dr. Barker was formerly Deputy Director of the National Cancer Institute (NCI), including founding co-chair of the NCI-FDA Interagency Task Force (IOTF) and founding co-chair of the Cancer Steering Committee of the FNIH Biomarkers Consortium (FNIH-BC). Prior to the NCI, she served as a senior scientist and executive at Battelle Memorial Institute and subsequently co-founded a public biotechnology company engaged in biomarker development. She is Co-Director of Complex Adaptive Systems (CAS) and Professor in the School of Life Sciences at ASU.  Dr. Barker completed her M.A. and Ph.D. at The Ohio State University.

Carolyn ComptonCarolyn Compton, M.D., Ph.D., Chief Medical Officer for the NBDA, works closely with external biomarker experts from all of the NBDA’s stakeholder communities to plan and execute specific programs and demonstration projects across the complex biomarker development continuum. She formerly served as the CEO of the Critical Path Institute, Director of Biorepositories and Biospecimen Research for the NCI, and Chair of the Department of Pathology at McGill University.  Dr. Compton received her M.D. and Ph.D. from Harvard University.

George PosteGeorge Poste, D.V.M., Ph.D., Interim Chief Science Officer, identifies key biomarker scientific and development problems and builds networks from affected biomarker stakeholders to plan and implement solution strategies. Dr. Poste founded and developed ASU’s Biodesign Institute and serves as Co-Director of Complex Adaptive Systems and Regents Professor at ASU. He was formerly Chief Science and Technology Officer and President, R&D, of SmithKline Beecham. Dr. Poste received his D.V.M., Ph.D., and D.Sc. from the University of Bristol, England.

Ken BuetowKen Buetow, Ph.D., Director of Bioinformatics and Data Management, oversees the development of the NBDA’s foundational infrastructure and programs in bioinformatics, data management, and computational programs.  He previously served as the Director of the Center for Biomedical Informatics and Information Technology for the NCI. Dr. Buetow is the Director for the Computational Sciences and Informatics Program for Complex Adaptive Systems and Professor in the School of Life Sciences at ASU.  He received his Ph.D. in Human Genetics from the University of Pittsburgh.